دورية أكاديمية
Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration
| العنوان: | Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration |
|---|---|
| المؤلفون: | Mrejen, S., Jung, J. J., Chen, C., Patel, S. N., Gallego-Pinazo, R., Yannuzzi, L. A., Xu, L., Marsiglia, M., Boddu, S., Freund, K. B. |
| المصدر: | Journal Articles |
| بيانات النشر: | Donald and Barbara Zucker School of Medicine Academic Works |
| سنة النشر: | 2015 |
| المجموعة: | Hofstra Northwell Academic Works (Hofstra Northwell School of Medicine) |
| مصطلحات موضوعية: | Treat and Extend Regimen, anatomical classification, choroidal neovascularization, fluorescein angiography classification, intravitreal anti-VEGF injections, neovascular age-related macular degeneration, Ophthalmology |
| الوصف: | With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with treatment-naive NVAMD initially classified based on fluorescein angiography (FA) alone or with an anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed over an average of 3.5 years (range 1-6.6) with a retention rate of 62.9%, and visual acuity significantly improved with a TER that required a mean number of 8.3 (+/-1.6) (+/- standard deviation) intravitreal anti-VEGF injections/year (range 4-13). The number of injections and the anatomic classification were independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1 neovascularization had better visual outcomes and received more injections than the other neovascular subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes. |
| نوع الوثيقة: | text |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | https://academicworks.medicine.hofstra.edu/publications/1635Test; https://academicworks.medicine.hofstra.edu/context/publications/article/2636/viewcontent/JClinMed2015v4p1380.pdfTest |
| DOI: | 10.3390/jcm4071380 |
| الإتاحة: | https://doi.org/10.3390/jcm4071380Test https://academicworks.medicine.hofstra.edu/publications/1635Test https://academicworks.medicine.hofstra.edu/context/publications/article/2636/viewcontent/JClinMed2015v4p1380.pdfTest |
| رقم الانضمام: | edsbas.972841CC |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/jcm4071380 |
|---|